SCHEMBL17300445

SCHEMBL17300445

CCCc1c(SCCCOc2ccc(C(C)O)c(C)c2C)ccc(C(C)=O)c1O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYSLTR2 Q9NS75 14/20 0.54
CYSLTR1 Q9Y271 14/20 0.54
PPARG P37231 4/20 0.54
PPARD Q03181 4/20 0.54
PPARA Q07869 4/20 0.54
LMNA P02545 2/20 0.46
CYP1A2 P05177 1/20 0.46
MAPT P10636 1/20 0.46
CYP2C9 P11712 1/20 0.46
NFKB1 P19838 1/20 0.46
BLM P54132 1/20 0.46
GRM2 Q14416 1/20 0.46
MEN1 O00255 1/20 0.45
GLA P06280 1/20 0.45
CYP3A4 P08684 1/20 0.45
ALOX5 P09917 1/20 0.45
ALOX15 P16050 1/20 0.45
TSHR P16473 1/20 0.45
PTGS1 P23219 1/20 0.45
PTGS2 P35354 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12281318 0.94 CYSLTR2 (0.56) CYSLTR2CYSLTR1PPARGPPARDPPARA
SCHEMBL18590691 0.90 CYSLTR2 (0.57) CYSLTR2CYSLTR1PPARGPPARDPPARA
SCHEMBL15032724 0.89 PPARG (0.60) CYSLTR2CYSLTR1PPARGPPARDPPARA
SCHEMBL9176648 0.87 CYSLTR2 (0.51) CYSLTR2CYSLTR1PPARGPPARDPPARA
SCHEMBL9178402 0.86 CYSLTR2 (0.64) CYSLTR2CYSLTR1PPARGPPARDPPARA
SCHEMBL12280239 0.85 PPARG (0.63) CYSLTR2CYSLTR1PPARGPPARDPPARA
SCHEMBL17771268 0.83 CYSLTR2 (0.39) CYSLTR2CYSLTR1PPARGPPARDPPARA
SCHEMBL17247293 0.82 CYSLTR2 (0.66) CYSLTR2CYSLTR1PPARGPPARDPPARA
SCHEMBL2419557 0.80 CYSLTR2 (0.62) CYSLTR2CYSLTR1PPARGPPARDPPARA
SCHEMBL17771267 0.79 CYSLTR2 (0.50) CYSLTR2CYSLTR1PPARGPPARDPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170065544-A1 METHOD OF TREATING IDIOPATHIC PULMONARY FIBROSIS MEDICINOVA, INC. (US) 2017-03-09 US disclosed
US-9498458-B2 Method of inhibiting or treating fibrosis MEDICINOVA, INC. (US) 2016-11-22 US disclosed
US-20150342913-A1 METHOD OF INHIBITING OR TREATING FIBROSIS MEDICINOVA, INC. 2015-12-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150342913-A1 METHOD OF INHIBITING OR TREATING FIBROSIS MMP1, COL1A1, CCL11 CYSLTR2 402/4885CYSLTR1 237/4885PPARG 931/4885
US-20170065544-A1 METHOD OF TREATING IDIOPATHIC PULMONARY FIBROSIS CCL11, CFTR, ELANE CYSLTR2 301/4885CYSLTR1 229/4885PPARG 793/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.